Fig. 3From: Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trialBody weight Change from baseline in body weight over time [mixed model repeated measures (MMRM) in the full analysis set (FAS), observed cases (OC)]Back to article page